ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TEVA Teva Pharmaceutical Industries Ltd

13.30
0.29 (2.23%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Teva Pharmaceutical Industries Ltd NYSE:TEVA NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.29 2.23% 13.30 13.30 12.76 12.76 8,522,328 23:57:03

ADRs End Mostly Higher; China Eastern, Teva Trade Actively

13/12/2017 11:30pm

Dow Jones News


Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Teva Pharmaceutical Indu... Charts.

International stocks trading in New York closed mostly higher on Wednesday.

 

The BNY Mellon index of American depositary receipts rose 0.4% to 151.27. The European index increased 0.3% to 140.86. The Asian index rose 0.7% to 178.36. The emerging-markets index rose 0.3% to 318.67, and the Latin American index fell 1.2% to 239.23. China Eastern Airlines Corp. (CEA) and Teva Pharmaceutical Industries Ltd. (TEVA) were among those with ADRs that traded actively.

 

Chinese airlines rose amid hopes that companies in the sector will be among the next batch to get fresh outside investment amid the government's so-called mixed-ownership reform. ADRs in China Eastern Airlines rose 4.3% to $30.88 and China Southern Airlines Co. (ZNH) rose 3.8% to $48.

 

ADRs in Teva fell 5% to $15.70 as the company said it would detail its restructuring plan and additional measures to improve its business Thursday morning. Media reports last week said that the company is considering cutting as many as 10,000 jobs.

 

ADRs of Sanofi SA (SNY) fell 0.1% to $43.92 after the company said it expects to begin at least 10 Phase 3 studies over the next 12 months, an announcement that came from a preview of its research-and-development strategy and pipeline for 2018.

 

(END) Dow Jones Newswires

December 13, 2017 18:15 ET (23:15 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Teva Pharmaceutical Indu... Chart

1 Year Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

1 Month Teva Pharmaceutical Indu... Chart

Your Recent History

Delayed Upgrade Clock